Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Pipeline Profile: Narrowing The Spectrum Of Drug Activity

Executive Summary

Development is most advanced in C. difficile infection, but US FDA's exploration of pathways to expedite single pathogen treatments could spur earlier-stage QIDP projects targeting Staphylococcus and Pseudomonas species.

Advertisement

Related Content

Polyphor Pursues Promise Of Inhaled Antibiotics To Tackle Lung Infections
Actelion Setback Ahead Of J&J Deal Closure
Flexible 'Menu' Of Antibacterial Development Options Suggested By US FDA Panel
Scrip Asks… Is The Microbiome Hype Or Happening?
Pfizer To Take Zinplava Rival Into Phase III For C Diff
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Merck’s C. Diff Drug Zinplava Clears FDA With Heart Failure Warning
US FDA Panel To Meet on Transplant IVDs, Test For Managing Antibiotics
Coordinating Antibiotics, Test Development Could Shorten Approval Times, US FDA Says
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC099051

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel